LENZ
NASDAQ
$4.96
LENZ Therapeutics Inc (LENZ)
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical unmet needs in the central nervous system (CNS). The company employs advanced drug formulation and delivery technologies to support a robust pipeline of proprietary assets, aiming to enhance patient outcomes and address significant healthcare challenges. With a strong focus on strategic partnerships and a commitment to rigorous clinical research, LENZ is strategically positioned for significant growth and aspires to become a key player in the biopharmaceutical landscape, leveraging emerging opportunities in the dynamic healthcare market.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $32 (+545.16%)
Market Cap
$156M
P/B Ratio
0.63
Free Cash Flow Yield
-55.89%
Beta (5Y)
1.54
Price Chart
Valuation
Market Cap$156M
P/S7.45
P/B0.63
Profitability
Total Revenue (TTM)$21M
Gross Profit (TTM)$19M
EBITDA-$118M
Operating Margin-2322%
EPS-$3.58
Financial Health
Free Cash Flow Yield-55.89%
Growth & Risk
Beta (5Y)1.54
Sharpe Ratio-2.03